Journal
ANTIVIRAL THERAPY
Volume 23, Issue 1, Pages 91-94Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP3173
Keywords
-
Categories
Funding
- Swiss National Science Foundation [PZ00P3-142411, BSSGI0_155851]
- Swiss National Science Foundation (SNF) [BSSGI0_155851, PZ00P3_142411] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Background: Despite being used by more than 18 million people our understanding of the extent of the effects of antiretrovirals on the human body and other organisms remains incomplete. In addition, the direct effect of antiretrovirals on the gut microbiota of HIV-infected individuals has been largely overlooked in microbiome studies concerned with HIV-infected individuals. Methods: Here we tested 25 antiretrovirals on Bacillus sub-tills and Escherichia coli using a broth microdilution assay to assess whether these drugs have an antibacterial effect. Results: We found that several widely used antiretroviral drugs have in vitro antibacterial activity against both gram-positive and gram-negative commensal bacteria. Efavirenz inhibited the growth of B. subtilis with a minimum inhibitory concentration (MIC) of 16 mu g/ml (in all three replicates), while 2',3'-dideoxyinosine and zidovudine inhibited the growth of E. coli with an MIC of 16-32 mu g/ml and 0.016-0.125 mu g/ml (respectively). Conclusions: Given the large and increasing number of individuals on antiretrovirals, and the lifelong nature of HIV treatment, this proof-of-concept report could have several potential implications, including an impact of antiretrovirals on bacterial coinfections, as well as potentials for drug discovery and repositioning.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available